SYNCOM FORMULATIONS (INDIA)
Quarterly Results Analysis [Sep2024]
SYNCOM FORMULATIONS (INDIA) Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹102 Cr | ₹87 Cr | ₹75 Cr | ₹65 Cr | ₹64 Cr | ₹60 Cr | ₹61 Cr | ₹57 Cr |
Expenses | ₹90 Cr | ₹77 Cr | ₹65 Cr | ₹58 Cr | ₹57 Cr | ₹53 Cr | ₹55 Cr | ₹51 Cr |
Operating Income | ₹12 Cr | ₹10 Cr | ₹9 Cr | ₹7 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr |
Other Income | ₹4 Cr | ₹1 Cr | ₹3 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹7 Cr | ₹2 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
Depreciation | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr |
Profit Before Tax | ₹15 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹8 Cr | ₹6 Cr | ₹10 Cr | ₹6 Cr |
Profit After Tax | ₹11 Cr | ₹8 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹4 Cr | ₹8 Cr | ₹4 Cr |
EPS | ₹0.12 | ₹0.08 | ₹0.08 | ₹0.07 | ₹0.07 | ₹0.05 | ₹0.09 | ₹0.04 |
Industry Peers & Returns | 1W | 1M | 1Y |
SYNCOM FORMULATIONS (INDIA) | 2.8% | -7.4% | 38.2% |
SUN PHARMACEUTICAL INDUSTRIES | 0.9% | 4.4% | 50% |
CIPLA | 2.1% | 0.2% | 22.8% |
DR REDDYS LABORATORIES | -1.1% | 12.1% | 18.1% |
ZYDUS LIFESCIENCES | 1.8% | 0.9% | 41.3% |
DIVIS LABORATORIES | 4.6% | -1.1% | 55.6% |
MANKIND PHARMA | 0.9% | 13.3% | 45.6% |
TORRENT PHARMACEUTICALS | 1.2% | 2.5% | 48.2% |
LUPIN | 7.6% | 15.1% | 78.8% |
SYNCOM FORMULATIONS (INDIA) Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 17.26 % |
Y-o-Y | 60.27 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹102 Cr | 17.26 | |
Jun2024 | ₹87 Cr | 17.01 | |
Mar2024 | ₹75 Cr | 14.48 | |
Dec2023 | ₹65 Cr | 2.04 | |
Sep2023 | ₹64 Cr | 6.69 | |
Jun2023 | ₹60 Cr | -1.87 | |
Mar2023 | ₹61 Cr | 6.27 | |
Dec2022 | ₹57 Cr | - |
SYNCOM FORMULATIONS (INDIA) Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 16.33 % |
Y-o-Y | 89.81 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹12 Cr | 16.33 | |
Jun2024 | ₹10 Cr | 10.93 | |
Mar2024 | ₹9 Cr | 28.06 | |
Dec2023 | ₹7 Cr | 14.86 | |
Sep2023 | ₹6 Cr | -0.82 | |
Jun2023 | ₹6 Cr | 8.39 | |
Mar2023 | ₹6 Cr | 0.91 | |
Dec2022 | ₹6 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -0.75 % |
Y-o-Y | 18.43 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 11.89% | -0.75 | |
Jun2024 | 11.98% | -5.22 | |
Mar2024 | 12.64% | 11.86 | |
Dec2023 | 11.3% | 12.55 | |
Sep2023 | 10.04% | -7.04 | |
Jun2023 | 10.8% | 10.54 | |
Mar2023 | 9.77% | -5.05 | |
Dec2022 | 10.29% | - |
SYNCOM FORMULATIONS (INDIA) Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 45.53 % |
Y-o-Y | 70.58 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹11 Cr | 45.53 | |
Jun2024 | ₹8 Cr | 3.11 | |
Mar2024 | ₹7 Cr | 5.71 | |
Dec2023 | ₹7 Cr | 7.54 | |
Sep2023 | ₹7 Cr | 48.13 | |
Jun2023 | ₹4 Cr | -48.11 | |
Mar2023 | ₹8 Cr | 104.39 | |
Dec2022 | ₹4 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 24.11 % |
Y-o-Y | 6.47 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 10.86 % | 24.11 | |
Jun2024 | 8.75 % | -11.88 | |
Mar2024 | 9.93 % | -7.63 | |
Dec2023 | 10.75 % | 5.39 | |
Sep2023 | 10.2 % | 38.78 | |
Jun2023 | 7.35 % | -47.08 | |
Mar2023 | 13.89 % | 92.38 | |
Dec2022 | 7.22 % | - |
SYNCOM FORMULATIONS (INDIA) Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 50.00 % |
Y-o-Y | 71.43 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹0.12 | 50.00 | |
Jun2024 | ₹0.08 | 0.00 | |
Mar2024 | ₹0.08 | 14.29 | |
Dec2023 | ₹0.07 | 0.00 | |
Sep2023 | ₹0.07 | 40.00 | |
Jun2023 | ₹0.05 | -44.44 | |
Mar2023 | ₹0.09 | 125.00 | |
Dec2022 | ₹0.04 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD